Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02016287
Other study ID # CGOG7002
Secondary ID CGOG7002
Status Recruiting
Phase Phase 2
First received December 7, 2013
Last updated December 13, 2013
Start date December 2013
Est. completion date July 2016

Study information

Verified date December 2013
Source Peking University
Contact Lin Shen, MD
Phone 86-10-88196561
Email lin100@medmail.com.cn
Is FDA regulated No
Health authority China: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Elderly patients with metastatic esophageal squamous cell carcinomas have poor prognosis and majority of them were intolerable to combined chemotherapy in China. In the investigators phase II clinical trial proceeded before, the paclitaxel treatment showed good tolerance and efficacy to esophageal squamous cell carcinomas. Radiotherapy has been indicated as a definitive treatment for unresectable or medically inoperable tumors in ESCC patients. However, not only the combination with chemotherapy, but also the boundaries of the clinical target volume (CTV) are not internationally defined. The investigators then initiated a prospective phase II clinical trial with sequential paclitaxel/cisplatin and radiotherapy as the 1st line treatment in elderly metastatic esophageal carcinoma to observe the efficacy and safety of the combination.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date July 2016
Est. primary completion date December 2015
Accepts healthy volunteers No
Gender Both
Age group 69 Years and older
Eligibility Inclusion Criteria:

1. Having signed informed consent Age more than 69 years old

2. Histologically confirmed esophageal squamous carcinoma,metastatic disease with primary tumor,no prior palliative chemotherapy;

3. No prior radiotherapy except radiotherapy at non-target lesion of the study more than 3 months

4. Sex is not limited

5. Measurable disease according to the RECIST criteria(diameter of the lesion should be more than 10mm by spiral CT or MRI, more than 20mm by common CT, the date of image should be less than 15 days before enrollment)

6. Karnofsky performance status =80

7. Life expectancy of = 3 month

8. WBC > 3,000/mm3, absolute neutrophil count =2000/mm3, platelet > 100,000/mm3, Hb > 9g/dl(within 14 days before enrollment),ALT and AST < 1.5 times ULN (=5 times ULN in patients with liver metastases),Bilirubin level < 1.0 times ULN,Serum AKP < 2.5 times ULN,Serum creatinine < 1.0 times ULN

9. No sever complication, such as active gastrointestinal bleeding, perforation, jaundice, obstruction, non-cancerous fever > 38?;

10. Normal ECG and heart function

11. Fertile patients must use effective contraception Good compliance

Exclusion Criteria:

1. Previous treatment of palliative chemotherapy

2. Known hypersensitivity to Paclitaxel,Cisplatin

3. Only with Brain or bone metastasis

4. No measurable lesions, eg. pleural fluid and ascites

5. Suffer from severe heart disease or disease with other important organs Chronic diarrhea or renal dysfunction

6. Other previous malignancy within 5 year, except non-melanoma skin cancer

7. Mentally abnormal or disable cognition,including CNS metastasis

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Other:
Sequential chemotherapy (paclitaxel 80mg/m2 d1,d8) and radiotherapy
Sequential paclitaxel chemotherapy and radiotherapy

Locations

Country Name City State
China Peking University Cancer Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Shen Lin

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other disease control rate 1 year No
Other adverse events 2 years Yes
Other quality of life 2 years No
Primary progression free survival the follow-up visit of PFS will be performed every 2 cycles 1 year No
Secondary overall survival OS means that from the first dose of treatment drug to death or lost, the follow-up visit will be performed every 3 months till death or lost 2 years No
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06025071 - Residual Inflammatory Risk-Guided colcHicine in Elderly Trial Phase 4
Recruiting NCT05939674 - Effects of Flumazenil on Recovery After Total Intravenous Anesthesia With Remimazolam N/A
Active, not recruiting NCT01862445 - Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients
Completed NCT04065763 - Correlation of the Dural Sac Dimension With the Spread of Spinal Anesthesia
Completed NCT06174168 - The Decisiveness of MFI-11 in Predicting Complications in Patients > 65 Years Who Underwent EBUS-TBNA Under Sedation
Completed NCT05103696 - A Comparative Study of Rimazolam and Propofol Combined With Etomidate in Gastroenteroscopy in Elderly Patients N/A
Active, not recruiting NCT05603364 - Effect of Postoperative Oral Carbohydrate Administration in Total Knee Arthroplasty Elderly Patients Early Phase 1
Terminated NCT03743961 - Geriatric Intervention Contribution on Quality of Life of Elderly Patients With Metastatic Neoplasia
Completed NCT00773942 - Design & Evaluation of a Medication Therapy Management Program to Improve Patient Safety in Medicare Beneficiaries N/A
Terminated NCT03324711 - Psychometric Validation of the "Antillanisée" Version of the Mini Mental State Examination (MMSEa) N/A
Completed NCT03211312 - Prediction Model of Cardiac Risk for Dental Extraction in Elderly Patients With Cardiovascular Diseases
Enrolling by invitation NCT04389008 - The Study of Anesthesia-related Risk Factors for Postoperative Death in Elderly Non-cardiac Surgery Patients in China
Completed NCT01851005 - Effect of Dexmedetomidine on Recovery Profiles of Elderly Patients N/A
Recruiting NCT04442412 - Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy Phase 3
Completed NCT02873533 - Modification of the Quality of Life Based on Objective Geriatric Tests N/A
Completed NCT01599676 - Citrulline, Exercise Training and Muscle Strength in the Elderly N/A
Completed NCT04209738 - Changes in Cardiovascular and Sleep Quality Parameters Under Eurythmy Therapy and Tai Chi in Comparison to Standard Care - A Substudy of the ENTAiER Trial
Recruiting NCT04321265 - Outcomes and Prognostic Factors in COVID-19
Recruiting NCT05242692 - The Effects of Subanesthetic S-ketamine on Postoperative Delirium and Cognitive Function in the Elderly Undergoing Non-cardiac Thoracic Surgery Early Phase 1
Completed NCT03868007 - Protective Effects of RIC in Elderly With Acute Ischemic Stroke Complicating Acute Coronary Syndrome N/A